D N A Of Biopreneur

362 views

Published on

What makes a successful entrepreneur in health care? Check this out. And join Biopreneur program at EDI,Ahmedabad

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
362
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

D N A Of Biopreneur

  1. 1. DNA of Biopreneur<br />A.S.Rao<br />Adviser-Innovation Clusters,FMC<br />indiainvents@hotmail.com<br />http://www.indiainvents.blogspot.com/<br />
  2. 2. Molecule millionaires<br />Scientist turned promoter: Dr Anji Reddy (DPR), Ketan R Patel(Troikka), Krishna Ella (Bharat Biotech), Ramanbhai Patel(Cadia), <br />Biopreneurs: Ranbir Singh & Gurbax Singh (Ranbaxy), UN Mehta (Torrent), Varaprasad Reddy (Shanta Biotech), Raghavendrarao (Orchid)<br />
  3. 3. Signature of success<br />Master the virtuous cycle of knowledge management.<br />Identify business opportunity, decipher key factors, relate to technology, acquire technology and raise the stock of Firm Specific Knowledge.<br />Learn to network with knowledge partners and knowledge workers.<br />Lead cluster formation as network orchestrator<br />
  4. 4. Knowledge cycle<br />
  5. 5. Opportunities<br />Patents not enforced in India<br />Drugs going off the patents<br />Affordable health care<br />100 global technologies shortlisted by knowledge partner Sky Quest.<br />
  6. 6. Patents not enforced in India<br />http://www.globalinnovationcommons.org<br />Buruli Ulcer, Dengue Fever, Dracunculiasis(Guinea Worm Disease), Leprosy, Lymphatic Filariasis, Malaria, Sickle Cell Anemia, Snake Bite, Spider Bite<br />
  7. 7. Going off the patent<br /> 22 drugs will go off-patent in India by 2015-Rituxan, an anti-neoplasticmAbs from Roche; Lantus, an antidiabetics from Sanofiaventis; and Neulasta, an immunostimulants from Amgen; have record sales of $5.6 billion, $4.3 billion and $3.4 billion respectively. Similarly, Epogen from Amgen, Avonex from Biogen Idec, Eprex from Johnson & Johnson and Rebif from Merck, which reported sales of over $2 billion in 2009, will lose patents by 2013.<br />
  8. 8. Affordable health care<br />Service innovations: Eye care, Heart surgery, Tele medicine, remote monitoring of patients,<br />Reverse innovations: from Innovators/ start-ups –Mosquito traps, infant warmers<br />Non-profit design centers: <br />http://www.d-rev.org/index.html<br />
  9. 9. Services needed<br />Technology search, access, acquisition, negotiation<br />Business plan<br />Regulatory approvals <br />
  10. 10. Biopreneur program<br />

×